Phase 1 Study to Evaluate the PK, Safety, and Tolerability of BG00012 in Chinese, Japanese, and Caucasian Healthy Volunteers

Inclusion Criteria: * Must give written informed consent and any authorizations required by local law * All subjects must practice effective contraception during the study and be willing and able to continue contraception for 30 days after their last dose of study treatment. Exclusion Criteria: * History of any clinically significant cardiac, endocrine, hematologic, hepatic, immunologic, metabolic, urologic, pulmonary, neurologic, dermatologic, psychiatric, and renal, or other major disease, as determined by the Investigator. * History of malignancy (subjects with basal cell carcinoma that has been completely excised prior to study entry remain eligible) * History of severe allergic or anaphylactic reactions * Known history of or positive test result for Human Immunodeficiency Virus (HIV) * Serious infection (e.g., pneumonia, septicemia) within 2 months prior to Screening. * Female subjects who are pregnant or currently breastfeeding